Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Tulkens, Paul M.
2013.
Will “Improbable Resistance” Become of Daily Concern?.
Infectious Diseases in Clinical Practice,
Vol. 21,
Issue. 2,
p.
75.
Bryant, Kendall A.
Roberts, Amity L.
Rupp, Mark E.
Anderson, James R.
Lyden, Elizabeth R.
Fey, Paul D.
and
Van Schooneveld, Trevor C.
2013.
Susceptibility of enterococci to daptomycin is dependent upon testing methodology.
Diagnostic Microbiology and Infectious Disease,
Vol. 76,
Issue. 4,
p.
497.
Wang, Guiqing
Kamalakaran, Sitharthan
Dhand, Abhay
Huang, Weihua
Ojaimi, Caroline
Zhuge, Jian
Yee, Leslie Lee
Mayigowda, Pramod
Surendraiah, Pavan Kumar Makam
Dimitrova, Nevenka
and
Fallon, John T.
2014.
Identification of a Novel Clone, ST736, among Enterococcus faecium Clinical Isolates and Its Association with Daptomycin Nonsusceptibility.
Antimicrobial Agents and Chemotherapy,
Vol. 58,
Issue. 8,
p.
4848.
Laishram, Shakti
Sahni, Rani D.
Anandan, Shalini
and
Balaji, Veeraragavan
2014.
Evaluation of the antimicrobial activity of daptomycin and linezolid against vancomycin-resistant Enterococcus spp. isolates in south India.
Journal of Global Antimicrobial Resistance,
Vol. 2,
Issue. 3,
p.
194.
Leather, Helen L.
and
Wingard, John R.
2015.
Thomas’ Hematopoietic Cell Transplantation.
p.
1038.
Barber, Katie E
King, S Travis
Stover, Kayla R
and
Pogue, Jason M
2015.
Therapeutic options for vancomycin-resistant enterococcal bacteremia.
Expert Review of Anti-infective Therapy,
Vol. 13,
Issue. 3,
p.
363.
Kelesidis, Theodoros
2015.
Origin ofde novodaptomycin non susceptible enterococci.
World Journal of Clinical Infectious Diseases,
Vol. 5,
Issue. 2,
p.
30.
CHOW, A.
WIN, N. N.
NG, P. Y.
LEE, W.
and
WIN, M. K.
2016.
Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors.
Epidemiology and Infection,
Vol. 144,
Issue. 12,
p.
2540.
Soule, D.
and
Climo, M. M.
2016.
A Clinician’s Guide to the Treatment of Vancomycin Resistant Enterococci Bacteremia and Endocarditis.
Current Treatment Options in Infectious Diseases,
Vol. 8,
Issue. 3,
p.
194.
Lewis, J.D.
Enfield, K.B.
Cox, H.L.
Mathers, A.J.
and
Sifri, C.D.
2016.
A single‐center experience with infections due to daptomycin‐nonsusceptible Enterococcus faecium in liver transplant recipients.
Transplant Infectious Disease,
Vol. 18,
Issue. 3,
p.
341.
Zasowski, Evan J.
Claeys, Kimberly C.
Lagnf, Abdalhamid M.
Davis, Susan L.
and
Rybak, Michael J.
2016.
Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections.
Clinical Infectious Diseases,
Vol. 62,
Issue. 10,
p.
1242.
Matono, Takashi
Hayakawa, Kayoko
Hirai, Risen
Tanimura, Akira
Yamamoto, Kei
Fujiya, Yoshihiro
Mawatari, Momoko
Kutsuna, Satoshi
Takeshita, Nozomi
Mezaki, Kazuhisa
Ohmagari, Norio
and
Miyoshi-Akiyama, Tohru
2016.
Emergence of a daptomycin-non-susceptible Enterococcus faecium strain that encodes mutations in DNA repair genes after high-dose daptomycin therapy.
BMC Research Notes,
Vol. 9,
Issue. 1,
Yim, Juwon
Smith, Jordan R.
and
Rybak, Michael J.
2017.
Role of Combination Antimicrobial Therapy for Vancomycin‐Resistant Enterococcus faecium Infections: Review of the Current Evidence.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
Vol. 37,
Issue. 5,
p.
579.
DiPippo, Adam J.
Tverdek, Frank P.
Tarrand, Jeffrey J.
Munita, Jose M.
Tran, Truc T.
Arias, Cesar A.
Shelburne, Samuel A.
and
Aitken, Samuel L.
2017.
Daptomycin non-susceptible Enterococcus faecium in leukemia patients: Role of prior daptomycin exposure.
Journal of Infection,
Vol. 74,
Issue. 3,
p.
243.
Woods, Robert J.
Patel, Twisha S.
Nagel, Jerod L.
Newton, Duane W.
and
Read, Andrew F.
2018.
Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.
Infection Control & Hospital Epidemiology,
Vol. 39,
Issue. 2,
p.
226.
Greene, Matthew H
Harris, Bryan D
Nesbitt, Whitney J
Watson, Marley L
Wright, Patty W
Talbot, Thomas R
and
Nelson, George E
2018.
Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid–Nonsusceptible Vancomycin-Resistant Enterococcus.
Open Forum Infectious Diseases,
Vol. 5,
Issue. 10,
Neudorfer, Katharina
Schmidt-Malan, Suzannah M.
and
Patel, Robin
2018.
Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.
Diagnostic Microbiology and Infectious Disease,
Vol. 90,
Issue. 1,
p.
58.
Foster, Rachel A.
Philavong, Kingsavanh Paul
Weissman, Sharon
Tang, Xiaonan
and
Bookstaver, P. Brandon
2018.
Oritavancin for the Treatment of Daptomycin Nonsusceptible Vancomycin-Resistant Enterococci Osteomyelitis.
Infectious Diseases in Clinical Practice,
Vol. 26,
Issue. 2,
p.
97.
M.S.S, Pradeep
Yarava, Saritha
and
Rao K, Vishnuvardhan
2020.
Daptomycin susceptibility in enterococci isolated from urinary samples in a tertiary care hospital.
IP International Journal of Medical Microbiology and Tropical Diseases,
Vol. 6,
Issue. 1,
p.
48.
Morley, Valerie J
Kinnear, Clare L
Sim, Derek G
Olson, Samantha N
Jackson, Lindsey M
Hansen, Elsa
Usher, Grace A
Showalter, Scott A
Pai, Manjunath P
Woods, Robert J
and
Read, Andrew F
2020.
An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen.
eLife,
Vol. 9,
Issue. ,